<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02717091</url>
  </required_header>
  <id_info>
    <org_study_id>NUDC1508</org_study_id>
    <nct_id>NCT02717091</nct_id>
  </id_info>
  <brief_title>Neoadjuvant FOLFIRINOX or Nab-paclitaxel With Gemcitabine for Borderline Resectable Pancreatic Cancer</brief_title>
  <official_title>Phase II Study of Neoadjuvant FOLFIRINOX or Nab-paclitaxel With Gemcitabine for Borderline Resectable Pancreatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nagoya University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nagoya University</source>
  <brief_summary>
    <textblock>
      The aim of this study is to clarify the efficacy and safety of neoadjuvant FOLFIRINOX and
      nab-paclitaxel + gemcitabine for borderline resectable pancreatic cancer.
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date>July 2015</start_date>
  <completion_date type="Anticipated">June 2020</completion_date>
  <primary_completion_date type="Anticipated">June 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>R0 resection rate</measure>
    <time_frame>3 months</time_frame>
    <description>surgery is supposed to be performed 3 months after the initiation of chemotherapy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>completion rate of chemotherapy</measure>
    <time_frame>3 months</time_frame>
    <description>chemotherapy is supposed to take 3 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>relative dose intensity</measure>
    <time_frame>3 months</time_frame>
    <description>chemotherapy is supposed to take 3 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adverse event</measure>
    <time_frame>3 months</time_frame>
    <description>chemotherapy is supposed to take 3 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tumor response</measure>
    <time_frame>3 months</time_frame>
    <description>tumor response to chemotherapy will be assessed based on Response Evaluation Criteria In Solid Tumor (RECIST). CR: Complete Response, PR: Partial Response, PD: Progression, SD: Stable Disease, NE: Not Evaluable</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>disease free survival</measure>
    <time_frame>3 years after the surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>3 years after the surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>surgical complication</measure>
    <time_frame>1 month after the surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of the tumor</measure>
    <time_frame>3 months</time_frame>
    <description>Chemotherapy is supposed to take 3 months. After the completion of chemotherapy, the quality of the tumor will be assessed by imaging findings, such as CT number and Standardized uptake value.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Borderline Resectable Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>FOLFIRINOX</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4 course of FILFIRINOX before surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GEM + nab-PTX</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 course of GEM + nab-PTX before surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FOLFIRINOX</intervention_name>
    <arm_group_label>FOLFIRINOX</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gemcitabine + nab-paclitaxel</intervention_name>
    <arm_group_label>GEM + nab-PTX</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Borderline resectable pancreatic cancer (based on NCCN guideline version 2.2015)

          2. first treatment for pancreatic cancer

          3. performance status 0 or 1

          4. adequate one marrow function

          5. adequate renal function

          6. obtained informed consent

        Exclusion Criteria:

          1. other active concomitant malignancies

          2. other severe medical conditions; contraindication of FOLFIRINOX, paclitaxel and
             gemcitabine

          3. pregnant women

          4. no informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 11, 2016</study_first_submitted>
  <study_first_submitted_qc>March 22, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 23, 2016</study_first_posted>
  <last_update_submitted>March 28, 2018</last_update_submitted>
  <last_update_submitted_qc>March 28, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 30, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Nagoya University</investigator_affiliation>
    <investigator_full_name>Junpei Yamaguchi</investigator_full_name>
    <investigator_title>Surgical Oncology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

